Patents by Inventor Feng-Jing Chen

Feng-Jing Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190134059
    Abstract: The disclosure is directed to fulvestrant formulations including suspensions of fulvestrant particles suitable for injection. The formulations can comprise fulvestrant particles having an LD Dv(10) less than about 3 microns, for example, between about 1 micron to about 3 microns, an LD Dv(50) less than about 35 microns, for example, between about 2 microns and about 35 microns, and an LD Dv(90) less than about 120 microns, for example, between about 4 microns and about 120 microns. The formulations can comprise fulvestrant particles having a CE Dv(90) less than about 200 microns, for example, between about 10 microns and about 200 microns, a CE Dv(50) less than about 60 microns, for example, between about 5 microns and about 60 microns, and a CE Dv(10) less than about 25 microns, for example, between about 1 micron and about 25 microns.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: Feng-Jing CHEN, Steven L. KRILL, Rama Abu SHMEIS
  • Publication number: 20180289710
    Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.
    Type: Application
    Filed: December 1, 2017
    Publication date: October 11, 2018
    Inventors: Feng-Jing CHEN, Steven L. Krill
  • Publication number: 20180264117
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharamaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: September 25, 2017
    Publication date: September 20, 2018
    Applicant: Lipocine Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad, Huiping Zhang, Chandrashekar Gillyar
  • Publication number: 20180125979
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly steroids, are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, preferably a vitamin E substance; and a surfactant. The synergistic effect between the hydrophobic drug and the vitamin E substance results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharamaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: July 26, 2017
    Publication date: May 10, 2018
    Applicant: Lipocine Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad, Huiping Zhang, Chandrashekar Gilyar
  • Publication number: 20170239250
    Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.
    Type: Application
    Filed: February 19, 2016
    Publication date: August 24, 2017
    Inventors: Feng-Jing Chen, Steven L. Krill
  • Publication number: 20160184435
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 30, 2016
    Applicant: Lipocine Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad, Huiping Zhang, Chandrashekar Giliyar
  • Publication number: 20160106840
    Abstract: The present invention is directed to aqueous bivalirudin compositions and methods of administration of such compositions. The aqueous bivalirudin compositions of the present invention have a pH of about 3 to about 5 and are substantially free of buffer. Further compositions of the present invention include bivalirudin compositions comprising at least one stabilizer having a pH of about 3 to about 5. Additional compositions of the present invention include bivalirudin compositions comprising at least one stabilizer substantially free of buffer. Compositions of the present invention also include bivalirudin compositions substantially free of buffer. The invention is also directed to methods of treatment comprising administering a bivalirudin composition of the present invention. The invention is further directed to the use of the bivalirudin compositions of the present invention as an anticoagulant in a patient in need thereof.
    Type: Application
    Filed: December 29, 2015
    Publication date: April 21, 2016
    Inventors: Feng-Jing Chen, Steven L. Krill
  • Publication number: 20160015649
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: June 5, 2015
    Publication date: January 21, 2016
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad, Huiping Zhang, Chandrashekar Gillyar
  • Publication number: 20150328317
    Abstract: The present invention is directed to aqueous bivalirudin compositions and methods of administration of such compositions. The aqueous bivalirudin compositions of the present invention have a pH of about 3 to about 5 and are substantially free of buffer. Further compositions of the present invention include bivalirudin compositions comprising at least one stabilizer having a pH of about 3 to about 5. Additional compositions of the present invention include bivalirudin compositions comprising at least one stabilizer substantially free of buffer. Compositions of the present invention also include bivalirudin compositions substantially free of buffer. The invention is also directed to methods of treatment comprising administering a bivalirudin composition of the present invention. The invention is further directed to the use of the bivalirudin compositions of the present invention as an anticoagulant in a patient in need thereof.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 19, 2015
    Inventors: Feng-Jing CHEN, Steven L. Krill
  • Publication number: 20150190458
    Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 9, 2015
    Inventors: Mathias BRAUN, Carl Alan BUSACCA, Feng-Jing CHEN, Edwin Louis GUMP, Jenness B. MAJESKA, Scott PENNINO, Fenghe QIU, Maria Fernanda VILLAGRA
  • Patent number: 9034831
    Abstract: Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 19, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Feng-Jing Chen, Robert J. Schwabe
  • Publication number: 20150064243
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fickstad, Huiping Zhang, Chandrashekar Giliyar
  • Publication number: 20150038532
    Abstract: A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 5, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Feng-Jing CHEN, Juan Francisco GEL, Maria Fernanda VILLAGRA
  • Publication number: 20140037719
    Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.
    Type: Application
    Filed: January 10, 2013
    Publication date: February 6, 2014
    Applicant: Boehringer Ingelheim International Gmbh
    Inventors: Mathias BRAUN, Carl Alan BUSACCA, Feng-Jing CHEN, Edwin Louis GUMP, Jenness B. MAJESKA, Scott PENNINO, Fenghe QIU, Maria Fernanda VILLAGRA
  • Patent number: 8460704
    Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: June 11, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael L. Cappola, Svetlana Sienkiewicz, Glenn Charles Snow, Feng-Jing Chen
  • Publication number: 20120101049
    Abstract: A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration.
    Type: Application
    Filed: November 18, 2009
    Publication date: April 26, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Feng-Jing Chen, Juan Francisco Gel, Maria Fernanda Villagra
  • Publication number: 20110160149
    Abstract: Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants.
    Type: Application
    Filed: July 6, 2010
    Publication date: June 30, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Feng-Jing CHEN, Robert J. SCHWABE
  • Publication number: 20110142945
    Abstract: Compositions and methods for providing hydrophobic active agents in a bioavailable form are disclosed and described. In one aspect of the invention, pharmaceutical composition containing a testosterone ester is provided. The composition includes a testosterone ester in both dissolved form and as undissolved particles and the dissolved form comprises at least 35 wt % of the testosterone ester present in the composition. The composition further includes a solubilizer and a stabilizer.
    Type: Application
    Filed: February 17, 2011
    Publication date: June 16, 2011
    Inventors: Feng-Jing Chen, Kathryn Gutke, Srinivasan Venkateshwaran, Mahesh V. Patel
  • Publication number: 20100278918
    Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.
    Type: Application
    Filed: June 4, 2008
    Publication date: November 4, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Michael L. Cappola, Svetlana Sienkiewicz, Glenn Charles Snow, Feng-Jing Chen
  • Publication number: 20100137271
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 3, 2010
    Applicant: LIPOCINE, INC.
    Inventors: FENG-JING CHEN, MAHESH V. PATEL, DAVID T. FIKSTAD, HUIPING ZHANG, CHANDRASHEKAR GILIYAR